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C E L L  B I O L O G Y
The stem/progenitor landscape is reshaped in a mouse 
model of essential thrombocythemia and causes  
excess megakaryocyte production
Daniel Prins1,2*, Hyun Jung Park1,2*, Sam Watcham1,2, Juan Li1,2, Michele Vacca3, Hugo P. Bastos1,2, 
Alexander Gerbaulet4, Antonio Vidal-Puig3,5, Berthold Göttgens1,2†, Anthony R. Green1,2†‡
Frameshift mutations in CALR (calreticulin) are associated with essential thrombocythemia (ET), but the stages at 
and mechanisms by which mutant CALR drives transformation remain incompletely defined. Here, we use single- 
cell approaches to examine the hematopoietic stem/progenitor cell landscape in a mouse model of mutant CALR- 
driven ET. We identify a trajectory linking hematopoietic stem cells (HSCs) with megakaryocytes and prospectively 
identify a previously unknown intermediate population that is overrepresented in the disease state. We also show 
that mutant CALR drives transformation primarily from the earliest stem cell compartment, with some contri-
bution from megakaryocyte progenitors. Last, relative to wild-type HSCs, mutant CALR HSCs show increases in 
JAK-STAT signaling, the unfolded protein response, cell cycle, and a previously undescribed up-regulation of 
cholesterol biosynthesis. Overall, we have identified a novel megakaryocyte-biased cell population that is in-
creased in a mouse model of ET and described transcriptomic changes linking CALR mutations to increased HSC 
proliferation and megakaryopoiesis.
INTRODUCTION
The myeloproliferative neoplasms are a family of clonal blood 
disorders characterized by overproduction of platelets [essential 
thrombocythemia (ET)], overproduction of red blood cells [poly-
cythemia vera (PV)], or bone marrow fibrosis [myelofibrosis (MF)]. 
The genetic bases for these diseases have largely been described: 
Mutations in JAK2 are found in 99% of PV and 50 to 60% of ET and MF 
cases, while frameshift mutations in CALR are responsible for 25 to 
40% of cases of ET and MF (1–3). Frameshift mutants of calreticulin 
(CALR) have a novel C terminus that acts as a rogue ligand for the 
thrombopoietin receptor, MPL, and activates Janus kinase–signal 
transducer and activator of transcription (JAK-STAT) signaling (4, 5). 
We recently described the generation of a mouse model of mutant 
CALR-driven ET that faithfully recapitulates the key phenotypes of 
the human disease, namely, increased numbers of cells throughout 
the megakaryocytic (MK) lineage, particularly platelets (6).
Hematopoiesis is classically modeled as a stepwise process be-
ginning with a multipotent hematopoietic stem cell (HSC), which is 
functionally defined by its capability to reconstitute multilineage 
hematopoiesis when transplanted into a myeloablated recipient (7). 
This HSC then transits through a series of intermediate stages with 
increasing lineage restriction to terminally differentiated blood cells 
(8, 9). However, newly popularized single-cell technologies such as 
single-cell RNA sequencing (scRNAseq) have reshaped our under-
standing of hematopoiesis and suggest that cells travel through a 
continuum of differentiation rather than a series of rigidly defined 
stages (10, 11). In a recent demonstration of the power of scRNAseq 
to untangle complex differentiation processes, it was used to inter-
rogate the transcriptomes of hematopoietic stem and progenitor 
cells (HSPCs) to identify novel intermediate populations within 
erythropoiesis, which could then be isolated and characterized via 
fluorescence-activated cell sorting (FACS) strategies (12).
While HSCs are traditionally defined to be capable of reconstituting 
all blood lineages in transplantation experiments, there is an increas-
ing body of evidence that some cells within the immunophenotypic 
HSC compartment already exhibit some lineage bias or restriction 
(13–15). Studies in mice have shown that MK and erythroid lineages 
may branch off before other myeloid and lymphoid lineages (16–18), 
and lineage tracing studies have shown the MK lineage to be the 
earliest generated from HSCs (19–23). A transposon-based lineage 
tracing strategy showed some tags to be shared between long-term 
HSCs (LT-HSCs) and megakaryocyte progenitors (MkPs) but not 
multipotent progenitors (MPPs), indicative of a direct pathway linking 
HSCs and MK bypassing MPP (19). We therefore asked whether our 
mouse model of mutant CALR-driven ET could allow us to interrogate 
the differences in the hematopoietic landscapes between wild-type 
(WT) and disease model mice, with a particular focus on MK trajectories.
RESULTS
scRNAseq identifies a novel cell population overproduced 
in mutant CALR mice
We generated scRNAseq data from FACS-sorted HSPCs [Lin− Sca1+ 
cKit+ (LSK) and Lin− Sca1− cKit+ (LK) populations] from a pair of 
WT and CALR DEL (knock-in of del52 allele) homozygous (HOM) 
littermate mice. After quality control, we retained 11,098 WT (5959 
LSK and 5139 LK) and 15,547 HOM (7732 LSK and 7815 LK) cells 
for downstream analysis. We began by defining highly variable genes, 
which we used to perform principal component analysis (PCA) and 
generate a k = 7 nearest-neighbor graph. Cells were then assigned to 
clusters by mapping onto a previously published dataset of 44,082 
LK cells (24), with manual annotation of clusters (fig. S1A). Cells 
from all major blood lineages can be seen and separate into distinct 
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trajectories. To determine which cells were over- or underrepresented 
in the CALR DEL HOM mouse, we compared relative numbers of cells 
from each genotype. The most notable changes in relative cell abun-
dance were increased numbers of cells in the HSC and MK clusters 
(fig. S1B), consistent with the increased platelet phenotype of our ET 
mouse model (6). We repeated the analysis on a second pair of WT 
and CALR DEL HOM littermate mice, in this case retaining 3451 
WT (972 LSK and 2479 LK) and 12,372 HOM (4548 LSK and 7824 
LK) cells for downstream analysis after quality control, and again 
observed an increase in cells in the HSC and MK clusters (fig. S1C).
To better understand the subgroups of cells within stem/progenitor 
cells, we chose to use partition-based graph abstraction (PAGA) 
(25) to visualize our data. This method generates a graph in which 
each node represents a group of closely related cells and edge weights 
correspond to the strength of connection between two nodes. We 
again compared relative abundances between WT and CALR DEL 
HOM mice and colored the nodes so red nodes are enriched in CALR 
mice, while blue nodes are underrepresented. We observed that the 
fine cluster that was most overrepresented in CALR DEL HOM 
mice (marked with an arrow) fell between the HSC and MK clusters 
in both repeats (Fig. 1A and fig. S1D). We plotted the expression of 
the MK markers Cd9, Itga2b (CD41), Mpl, Pf4, and VWF in our PAGA 
and hypothesized two MK trajectories, as indicated by the green 
and blue arrows (fig. S1E). As the fine cluster most overrepresented 
in CALR DEL HOM mice would be an intermediate on one of these 
trajectories (green arrow), we further hypothesized that these cells 
would be of particular relevance in the disease setting of mutant 
CALR-driven ET and thus aimed to further study them.
We examined the expression of a series of genes typically used to 
FACS isolate different hematopoietic populations and found this fine 
cluster to be CD48−, EPCR− (Procr), and CD150+ (Slamf1) (Fig. 1B). 
We designed an immunophenotypic scheme to identify and isolate 
cells from this fine cluster, defining them to be Lin−, CD150+, CD48−, 
EPCR−, and CD45+. On the basis of our subsequent characteriza-
tion of these cells, we eventually termed them “proliferative MkPs” 
or pMKPs. Consistent with our transcriptomic data, when compar-
ing WT mice to CALR mutant mice, we found an increase in the 
frequency of pMKPs in CALR DEL HOM mice as assayed by flow 
cytometry (Fig. 1, C and D). We also found that pMKPs were ex-
panded in CALR DEL HET mice, albeit to a lesser extent than ob-
served in CALR DEL HOM mice (fig. S1F).
pMKPs are proliferative and MK-biased
To characterize pMKPs, we FACS-sorted single ESLAM (EPCR+ SLAM) 
HSCs (Lin− CD45+ CD48− CD150+ EPCR+) (26), pMKPs (Lin− CD45+ 
CD48− CD150+ EPCR−), and MkPs (Lin− Sca1− cKit+ CD41+ CD150+) 
(27) (fig. S2A) from WT mice into individual wells of a 96-well plate 
and observed them every day for 4 days. We analyzed our sort data 
and observed that in pMKPs, markers traditionally used to define 
MkPs were Sca1−/lo/mid, cKit+, and CD41mid/+ (fig. S2B). pMKPs 
were additionally CD9+ and MPL+ (fig. S2C). On each day, we 
classified each well with surviving cell(s) into one of four categories, 
using cell size as a proxy for megakaryopoiesis (28–30): (i) exactly 
one large cell, presumed to be a megakaryocyte; (ii) multiple large 
cells; (iii) mixed expansion, with both large and small cells; and (iv) 
expansion with only small cells (Fig. 2A). To verify that larger cells 
represented MK cells, using cells from day 4 ESLAM, pMKP, and 
MkP colonies, we quantified average CD41 intensity via immuno-
fluorescence and classified cells as small or large via bright-field mi-
croscopy, using a small/large dichotomy assessed via bright-field 
microscopy to match the classification scheme used in Fig. 2A. Here, 
we confirmed that large cells have significantly higher CD41 stain-
ing, supporting their identification as MK (fig. S2D). In some cases, 
particularly large cells within mixed colonies showed very high CD41 
staining and membrane extensions that resembled proplatelets (repre-
sentative picture is shown in fig. S2E). Furthermore, we sorted pMKPs 
from VWF (von Willebrand factor)–green fluorescent protein–positive 
(GFP+) mice and found that large cells had a very bright VWF-GFP 
signal, supporting their identification as MK. Smaller cells in these 
clones had a much dimmer VWF-GFP signal, suggesting that they 
likely represent more immature cells that have not progressed as 
far through megakaryopoiesis (fig. S2F).
The vast majority of ESLAMs showed expansion with only small 
cells at day 4, consistent with being highly primitive HSCs with consid-
erable proliferative potential, but not yet producing megakaryocytes. 
Similarly, as predicted for MkPs, more than 95% of wells showed 
exclusively production of MKs at day 4, with the majority produc-
ing only one MK. This lack of in vitro proliferation for single MkPs is 
consistent with previously published results, where 75% of MkPs 
did not divide and none produced more than 10 MKs (31). pMKPs 
exhibited an intermediate phenotype: While approximately 90% of 
wells showed production of some MKs, they were much more likely 
to produce multiple MK than were MkPs. In particular, pMKPs fre-
quently proliferated into mixed colonies with both large and small 
cells, a behavior that was rarely seen for either ESLAMs or MkPs 
(Fig. 2B). Kinetic analysis showed that MkPs were faster to begin 
megakaryopoiesis than were pMKPs (Fig. 2C), and when consider-
ing only wells that produced only MKs, pMKPs produced more MKs 
than did MkPs (Fig. 2, D and E). pMKPs maintained their MK bias 
even when incubated under pro-erythroid or pro-myeloid conditions 
(fig. S3A). Culturing cells with thrombopoietin (THPO) increased the 
proportion of pMKPs that formed colonies with multiple MKs while 
reducing the number of mixed colonies (fig. S3B). To verify that our 
observed MK bias is not simply due to culture conditions support-
ing only megakaryopoiesis, we cultured ESLAMs under the same 
conditions for 10 days followed by flow cytometric analysis and ob-
served multilineage differentiation (fig. S3C).
To examine the extent of overlap between our pMKPs and tradi-
tionally defined MkPs, we stained bone marrow with a panel incor-
porating all necessary markers and index sorted single pMKPs and 
MkPs. On the basis of index sort values, 97% of MkPs were CD45+, 
50% were EPCR−, and only 2% were CD48−; when taken together, 
fewer than 1% of immunophenotypic MkPs also fell within the pMKP 
gate (fig. S3D); thus, pMKPs and MkPs can be FACS-separated on 
the basis of CD48− and EPCR−. In contrast, we found that an aver-
age of 51% of pMKPs were also immunophenotypically MkPs (CD41+ 
Sca1− cKit+) (fig. S3E). As we observed a partial overlap between 
pMKPs and MkPs, we used our index sort data to assign each pMKP 
an overlap score based on the levels of CD41, Sca1, and cKit: 1/3 if 
only one marker overlapped, 2/3 if two overlapped, and 3/3 for pMKPs 
that also fall within the MkP immunophenotypic gate. No pMKPs 
had an overlap score of 0/3. We used the same classification scheme 
as in Fig. 2B and found that lower overlap scores correlated to a more 
proliferative, less MK-restricted phenotype: The pMKPs that are least 
similar to MkPs are the most proliferative and the least restricted to 
the MK lineage, although they still display a strong preference for 
MK production (fig. S3F). pMKPs with the lowest overlap score 
took the longest to enter megakaryopoiesis (fig. S3G). Together, our 
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data indicate that pMKPs represent a group of cells with an MK bias 
and an increased proliferative potential as compared to traditionally 
defined MkPs.
pMKPs show limited and short-term contribution 
to platelets in transplants
We next determined whether pMKPs were capable of producing 
platelets in vivo. We made use of CD45.2 VWF-GFP donor mice and 
cKit W41/W41 CD45.1 recipient mice, which allowed us to track 
platelets (via VWF-GFP) and nucleated cells (by CD45.1/CD45.2 
staining) (Fig. 3A). We FACS-sorted ESLAMs, pMKPs, and MkPs 
from VWF-GFP donor mice and transplanted 30, 60, or 120 cells per 
recipient into sublethally irradiated W41 mice along with 250,000 
spleen MNCs (mononuclear cells) (SPMNCs) as helper cells and 
assayed peripheral blood chimerism every week for 4 weeks and at 
16 weeks. We did not sort on VWF-GFP+ at this stage, but flow cy-
tometry analysis showed that ESLAMs, pMKPs, and MkPs were all 
highly enriched for VWF-GFP expression when compared to total 
bone marrow (fig. S4A). We also transplanted one mouse per cohort 
with 250,000 SPMNCs alone to serve as a negative control to help 
with gating to avoid false positives. Representative gating strategies 
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Fig. 1. An MK trajectory is increased in CALR DEL HOM mice. (A) PAGA of scRNAseq data from WT and CALR DEL HOM mice. Red nodes represent those present at 
increased abundance in CALR DEL HOM mice, while blue nodes represent those at reduced abundance. The most highly enriched node is noted with an arrow. (B) RNA 
expression of the flow cytometry markers CD48, EPCR (Procr), and CD150 (Slamf1) plotted on PAGA graphs from (A). Cells within our node of interest (marked with an 
arrow) are CD48−, EPCR−, and CD150+. (C) Representative plots of SLAM cells from WT and CALR DEL HOM mice. CALR DEL HOM mice show higher numbers of both 
ESLAMs (Lin− CD48− CD150+ CD45+ EPCR+) and pMKPs (Lin− CD48− CD150+ CD45+ EPCR−). FITC, fluorescein isothiocyanate; PE, phycoerythrin. (D) Quantification of bone 
marrow frequency of pMKPs in WT and CALR DEL HOM mice. The frequency of pMKPs within live bone marrow mononuclear cells (BMMNCs) is significantly increased in 
CALR DEL HOM mice (WT, n = 3, 0.00029 ± 0.00008; HOM, n = 3, 0.0025 ± 0.0008; *P = 0.042).
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generate relatively high levels of platelets at all three cell doses, start-
ing with a very low level at week 1 and increasing over the course 
of 4 weeks and continuing up to 16 weeks (although one recipient 
of 30 ESLAMs was lost to follow-up before the 16-week time point). 
pMKPs and MkPs were only able to reconstitute platelets at a very 
low level (1/105 to 1/104), even at the highest cell dose (Fig. 3, B to D 
and summarized in E). Low levels of donor-derived platelets were 
detected in 10 of 12 pMKP recipients and 8 of 13 MkP recipients 
within the first 4 weeks; extended observation up to 16 weeks 
showed that few recipients continued to produce VWF-GFP+ plate-
lets, although all 3 pMKP recipients at the highest dose still showed 
VWF-GFP+ platelets. ESLAMs successfully produced CD11b+ my-
eloid cells in 10 of 10 recipients across varying cell doses, while pM-
KPs and MkPs only produced CD11b+ cells at a low level in 3 of 12 
and 2 of 10 recipients, respectively (fig. S4, D to F and summarized 
in G). Therefore, we concluded that while pMKPs and MkPs have 
limited capabilities in a transplantation experiment, they both show 
an MK bias, in agreement with their in vitro behaviors. These low 
levels of reconstitution suggest that pMKPs and MkPs do not divide 
























1 MK >1 MK Mixed Prolif only
****
Fig. 2. pMKPs are MK-biased and proliferative in vitro. (A) Representative pictures of in vitro culture output of single ESLAMs, pMKPs, and MkPs into four categories: 
1 MK, >1 MK, mixed, or proliferation only. (B) Classification of in vitro culture output of single ESLAMs, pMKPs, and MkPs at day 4 after FACS isolation. ESLAMs almost exclu-
sively proliferated without producing megakaryocytes, while MkPs almost exclusively produced MKs, usually producing only a single MK. pMKPs showed a strong MK bias 
but were more likely to proliferate than were MkPs. ESLAMs, n = 306 wells from five experiments; pMKPs, n = 291 wells from six experiments; MkPs, n = 235 wells from five 
experiments. Chi-square test, ****P < 0.0001. (C) Timing of megakaryopoiesis in ESLAMs, pMKPs, and MkPs. Individual cells were observed for 4 days after sort, and the first 
date on which cell(s) showed signs of megakaryopoiesis was noted. MkPs were faster to begin megakaryopoiesis than were pMKPs (at day 2, MkPs: 89.5 ± 0.7%; pMKPs: 
50 ± 6%; *P = 0.02). ESLAMs, n = 5; pMKPs, n = 6; MkPs, n = 5. (D) Log2-transformed cell counts of megakaryocytes from pMKPs and MkPs after 4 days of culture. Each point 
represents the average value from one of four separate experiments. Average of four experiments: pMKP, 1.12; MkP, 0.412, *P = 0.0295. (E) Histogram of the minimum 
number of cell divisions for 103 pMKPs and 158 MkPs that produced only megakaryocytes after 4 days of culture across four experiments. Chi-square test, ***P = 0.0001.
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pMKPs are produced from HSCs in an  
MPP2-independent manner
Our single-cell transcriptomic analysis showed pMKPs to be an in-
termediate stage on an MK trajectory maintaining CD48 negativity 
(Fig. 1B and green arrow in fig. S1E), which suggests that they by-
pass the traditional MPP2 pathway (blue arrow in fig. S1E). We there-
fore asked whether we could show production of pMKPs from HSCs 
in an MPP2-independent manner by making use of a mouse model 
allowing inducible depletion of HSPCs. In this model, Tal1-Cre/
ERT mice are crossed with R26DTA mice, wherein treatment with 
tamoxifen leads to specific expression of diphtheria toxin in HSCs 
and primitive progenitors and hence suicidal depletion of these ear-
ly populations (Fig. 4A) (32). Within 6 weeks after HSC depletion, 
very few LT-HSCs remain, but levels of MPPs, committed progeni-
tors, and mature blood cells are only slightly lower than in control 
animals (32). We reasoned that if pMKPs arise directly from HSCs, 
they should be depleted to a similar extent as HSCs, while if they 
arise from an MPP pathway, they should be depleted to a similar 
extent as MPPs (i.e., to a lesser extent than HSCs).
We compared mice carrying either no Cre or Tal1-Cre/ERT after 
treatment with tamoxifen to induce specific depletion of HSCs. We 
observed a depletion of approximately 75% in the numbers of HSCs 
[whether using ESLAM markers or LT-HSC (LSK CD48− CD150+) 
markers] and a 68% reduction in the numbers of pMKPs in HSC- 
depleted mice. By contrast, there was no significant reduction in 
MPP2 or preMegE populations, while MkPs were reduced by ap-
proximately 51% (Fig. 4B). Consistent with previously published results, 
we observed no statistically significant reduction in other multipotent 
populations, including MPP3 and MPP4 (33), and committed progenitor 
populations, including CFU-E (erythroid colony- forming units), 
pCFU-E, pGM (pre-granulocyte/macrophage), and GMP (granulocyte/
monocyte progenitors) (fig. S5) (27). We noted that one Cre− mouse 
was an outlier, with noticeably higher frequencies of almost all pro-
genitor populations, and tested removing this outlier to ensure 
our conclusions were not unduly relying on this mouse. With the 
outlier removed, we calculated reductions of 68% in ESLAMs 
(P = 0.0001), 60% in pMKPs (P = 1.5 × 10−5), and an increase of 
24% in MPP2 (P = 0.50). Our analysis is therefore robust to the re-
moval of this outlier and demonstrates that the reduction in pMKP 
levels correlates more closely to that of ESLAMs than that of MPP2. 
Together, these data support a model in which pMKPs are pro-
duced from HSCs in an MPP2-independent manner and MkPs 
can be generated from pMKPs or via MPP2, accounting for their 









PB analysis at 
weeks 1, 2, 3, and 4
C
D
 ESLAM pMKP MkP 
30 cells 5/5 5/5 3/6 
60 cells 3/3 2/4 2/4 
120 cells 2/2 3/3 3/3 
 
E
2.5 × 105 helper
SPMNC
B
Fig. 3. pMKPs have limited platelet potential in transplantations. (A) Schematic of VWF-GFP+ transplantation strategy. ESLAMs, pMKPs, and MkPs were sorted from 
VWF-GFP+, CD45.2 donor mice and transplanted into sublethally irradiated cKit W41/W41 CD45.1 recipients. PB, peripheral blood. (B) Platelet reconstitution from 30 donor 
cells. (C) Platelet reconstitution from 60 donor cells. (D) Platelet reconstitution from 120 donor cells. (E) Table summarizing numbers of mice with successful platelet 
production from ESLAMs, pMKPs, and MkPs. Here, transplanted cells were defined to have produced platelets if platelets were observed at a level of at least 1 in 105 at 
one or more time points within the first 4 weeks after transplantation.
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CALR DEL drives platelet bias and proliferation at  
multiple stages
After characterizing the pMKP population in WT mice, we next asked 
whether there were qualitative differences between WT and CALR 
DEL HOM cells along the MK trajectory and not solely a quantita-
tive difference. To do so, we sorted single ESLAMs, pMKPs, and 
MkPs from WT and CALR DEL HOM mice and monitored their 
in vitro behavior over 4 days. While very few WT ESLAMs showed 
any MKs within the first 4 days after sort, a higher proportion of CALR 
DEL HOM ESLAMs showed MKs within mixed colonies (Fig. 5A). 
CALR DEL HOM pMKPs showed similar proportions of wells in 
each category (Fig. 5B), while CALR DEL HOM MkPs were more 
likely to form multiple MKs and less likely to form a single MK 
(Fig. 5C). To assess the statistical significance of these differences, 
using a Fisher’s exact or chi-square test required consolidation of 
our data into fewer categories, as some categories contained values 
that were too low (for example, for day 4 ESLAMs, the categories 
“1 MK” and “>1 MK” were 0 in both WT and HOM). We thus con-
solidated ESLAM data into two categories—“no MK” and “MK” 
(Fig. 5D)—and pMKP and MkP data into three categories—1 MK, 
>1 MK, and “mixed + prolif only” (Fig. 5, E and F). This showed 
that CALR DEL HOM ESLAMs were significantly more likely to 
form MKs (Fig. 5D). CALR DEL HOM pMKPs showed no statistically 
significant difference, suggesting no change in their MK bias or pro-
liferative behavior compared to WT pMKPs (Fig. 5E). CALR DEL 
HOM MkPs were significantly more proliferative than were WT MkPs 
(Fig. 5F). We also extended our observation of ESLAM clones to 
day 7 and observed an even stronger increase in the production of 
megakaryocytes from CALR DEL HOM ESLAMs, an increase noted 
both in wells producing mixed clones and in those producing MK-only 
clones (Fig. 5, G and H).
We also considered log2-transformed cell counts from those wells 
with exclusively megakaryocytes (i.e., 1 MK and >1 MK). In some 
cases, we observed the death of a cell or cells over our 4-day obser-
vation period; to account for cell death, we used the maximum num-
ber of cells observed over these 4 days. Mann-Whitney U tests showed 
no significant difference for pMKPs but a significant increase in MK 
production from CALR DEL HOM MkPs (fig. S6, A and B). Simi-
larly, calculations of the minimum number of divisions required to 
produce the observed number of MKs found no difference for pMKPs 
but a significant shift to more divisions from CALR DEL HOM 
MkPs (fig. S6, C and D). We also cultured ESLAMs in vitro and as-
sayed for the production of pMKPs, finding that CALR DEL HOM 
ESLAMs gave rise to significantly more pMKPs than did their WT 
counterparts (Fig. 5I). Together, we conclude that CALR DEL is act-
ing at multiple stages of megakaryopoiesis, promoting an MK bias 
from the earliest HSC compartments and increased proliferation at 
both HSC and MkP levels. While pMKPs are increased in number 
in CALR DEL HOM mice, these cells do not show altered proliferation 
or MK bias in vitro.
Transcriptomic analysis of CALR mutant cells shows 
dysregulated cholesterol biosynthesis
Last, we made use of our scRNAseq data to compare gene expression 
between WT and CALR DEL HOM cells along the MK trajectory. 
We considered cells within 2 of the 13 clusters defined by our tran-
scriptomic data (HSC and MK; fig. S1A) and 1 fine cluster (pMKP; 
arrow in Fig. 1A) (Fig. 6, A to C). As the pMKP fine cluster had fewer 
cells (24 in WT and 247 in CALR DEL HOM) than the larger HSC 
and MK clusters, we were only able to confidently call a small num-
ber of differentially expressed genes (DEGs) within this cluster. We 
performed Ingenuity Pathway Analysis (IPA) to determine which 
biological pathways and upstream regulators were most affected in 
the HSC and MK clusters; the small numbers of DEGs in pMKPs 
resulted in no statistically significant hits via IPA. The most affected 
canonical pathways fell into three broad groups: cell cycle (in blue), 
unfolded protein response (gold), and cholesterol biosynthesis (green) 
(Fig. 6, D and E). Full lists of canonical pathways, P values, and z 
scores are available in tables S1 (HSC) and S2 (MK). Genes contributing 
A
Tal1-CreERT/R26DTA







Fig. 4. pMKPs originate from HSCs in a MPP2-independent manner. (A) Schematic 
of DTA (diphtheria toxin fragment A) HSC depletion model experiment. Tal1-CreERT/
R26DTA mice were treated with four doses of tamoxifen at 0.1 mg/g to induce 
suicidal depletion of HSCs and then euthanized after 6 weeks for bone marrow 
(BM) analysis. (B) Frequencies of stem and progenitor cells with or without stem 
cell depletion. Cell populations that were significantly diminished by suicidal de-
pletion of HSCs include ESLAMs (Cre−, 17.1 ± 10.8/105 BMMNC; Cre+, 4.3 ± 2.0/105 
BMMNC; *P = 0.012), LTHSCs (LSK CD48− CD150+) (Cre−, 15 ± 12/105 BMMNC; Cre+, 
3.6 ± 1.7/105 BMMNC; *P = 0.031), pMKPs (Cre−, 13.0 ± 7.6/105 BMMNC; Cre+, 4.1/105 
BMMNC; *P = 0.013), and MkPs (Cre−, 44.2 ± 26.4/105 BMMNC; Cre+, 21.4 ± 6.1/105 BMMNC; 
*P = 0.046); Cre−, n = 8 and Cre+, n = 10. MPP2 (Cre−, 25.1 ± 29.1/105 BMMNC; Cre+, 
13.3 ± 3.6/105 BMMNC; P = 0.48) and preMegE (Cre−, 90.0 ± 62.9/105 BMMNC; Cre+, 
73.9 ± 29.6/105 BMMNC; P = 0.66) populations were depleted to lesser extents that 
did not reach statistical significance; Cre− n = 4 and Cre+ n = 6. ns, not significant.
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to these three pathways are highlighted in the same colors in Fig. 6, 
A to C; we note that pMKPs also show up-regulation of several UPR 
(unfolded protein response)– associated genes—such as Hspa5, Pdia3, 
and Pdia6—in addition to two known STAT targets (Ifitm2 and Socs2).
While cell cycle and UPR have previously been described as up- 
regulated in human CD34+ cells with CALR mutation (34), the dis-
covery of cholesterol biosynthesis was somewhat unexpected. However, 
this aligned with the predicted significant activation of the lipid and 
cholesterol biosynthetic transcriptional machinery controlled by 
the sterol regulatory element–binding proteins (SREBPs; SREBF1 
and SREBF2) and the SREBF chaperone (SCAP) and their inhibitor 
insulin-induced gene 1 (INSIG1) (Fig. 6F). Moreover, as discussed 
further below, a role for cholesterol biosynthesis in a proliferative, 
platelet-biased blood disorder is biologically plausible. Upstream 
regulator analysis also pointed to activation of ERN1 (Ire1) and 










Fig. 5. Mutant CALR drives an MK phenotype primarily from HSCs. (A) Classification of in vitro culture output of single ESLAMs from WT and CALR DEL HOM mice at 
day 4, using the classification scheme as in Fig. 2A. WT, n = 223; HOM, n = 225. (B) Classification of in vitro culture output of single pMKPs from WT and CALR DEL HOM mice 
at day 4; WT, n = 117; HOM, n = 161. Chi-square test P = 0.9201. (C) Classification of in vitro culture output of single MkPs from WT and CALR DEL HOM mice at day 4; WT, 
n = 136; HOM, n = 152. (D) Reclassification of data from (A) into two categories (MK or no MK) for a Fisher’s exact test, *P = 0.0191. (E) Reclassification of data from (B) into 
three categories (1 MK, >1 MK, and mixed + prolif only) for a chi-square test, P = 0.8183. (F) Reclassification of data from (C) into three categories (1 MK, >1 MK, and mixed + 
prolif only) for a chi-square test, **P = 0.0069. (G) Classification of in vitro culture output of single ESLAMs at day 7; WT, n = 136; HOM, n = 152. (H) Reclassification of data 
from (G) into two categories (MK or no MK) for a Fisher’s exact test, **P = 0.0014. (I) pMKPs as a proportion of live cells generated from in vitro culture of WT and CALR DEL 
HOM ESLAMs, assessed at day 3. WT, 0.062 ± 0.015; HOM, 0.193 ± 0.036, *P = 0.0135, n = 3 independent mice.
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B CHSC pMKP MK
Fig. 6. Mutant CALR affects STAT signaling, protein folding, cell cycle, and cholesterol biosynthesis. (A to C) Volcano plots showing DEGs between WT and CALR 
DEL HOM cluster 3 (HSC) (A), pMKP fine cluster (B), and cluster 11 (MK) (C). Genes within certain representative Gene Ontology (GO) terms are colored: regulation of 
cholesterol biosynthetic process (GO:0045540) (green), response to ER stress (GO:0034976) (gold), and regulation of mitotic cell cycle (GO:0007346) (blue). Other DEGs are 
colored in red. (D and E) Bar graphs showing z scores for up-regulated canonical pathways in cluster 3 (HSC) (C) and cluster 11 (MK) (D), filtered by P < 0.01 and z score of 
>1 or <−1. Bars are highlighted in green for cholesterol biosynthesis, gold for ER stress/unfolded protein response, or blue for cell cycle. (F) Upstream regulator analysis. 
Hits were filtered by P < 0.01. Bar graph showing the 10 most up-regulated and 10 most down-regulated predicted upstream regulators, when comparing WT and CALR 
DEL HOM cluster 3 (HSC) (blue) and cluster 11 (MK) (red), as measured by combining the z scores from WT and MK analyses.
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is consistent with previous demonstrations that mutant CALR acts 
via STAT signaling (4, 35–37). We additionally observed other previ-
ously undescribed signaling processes to be predicted to be activated, 
including drivers of proliferation such as CSF2 [granulocyte-macrophage 
colony-stimulating factor (GM-CSF)] and hepatocyte growth factor 
(HGF), or repressed, like the known tumor suppressors TP53 and let-7.
DISCUSSION
Single-cell transcriptomic approaches have allowed detailed exam-
inations of differentiation landscapes in both normal and perturbed 
hematopoiesis without a requirement to initially define populations 
based on a set of cell surface markers. We therefore used single-cell 
transcriptomics to investigate our recently generated mutant CALR- 
driven mouse model of ET and found an expected increase in both HSCs 
and MK lineage cells. We also found an increase in a previously unknown 
group of cells, here termed pMKPs, linking HSCs with the MK lineage. 
In vitro, pMKPs displayed behaviors intermediate to those of HSCs 
and MkPs: Similarly to HSCs, they had some proliferative potential, 
but similarly to MkPs, they were almost exclusively restricted to the 
MK lineage. In transplantations, pMKPs and MkPs showed similar 
behavior: They both transiently produced platelets at a low level. We 
hypothesize that while pMKPs are more proliferative than MkPs 
in vitro, neither population is capable of sufficient proliferation to 
significantly contribute to platelet production in the transplant set-
ting. While this manuscript was in preparation, another group de-
scribed separating SLAM (Lin− CD48− CD150+) cells based on EPCR 
and CD34, finding that EPCR− SLAM cells performed poorly in 
transplants and showed gene expression profiles (high Gata1, Vwf, 
and Itga2b) indicative of MK bias (38), results that are broadly con-
sistent with our own.
Our characterization of pMKPs accords well with an increasing 
understanding that at least a portion of megakaryopoiesis occurs 
via an early branch point directly from HSCs. While the standard 
model of hematopoiesis shows megakaryocytes subsequent to MPP2, 
lineage tracing experiments have shown that some MkPs are generated 
in an MPP2-independent way (19). Furthermore, in vivo labeling of 
the most primitive HSCs showed that within 1 week of label induc-
tion in LT-HSCs, label can be seen in MK lineages but no other, 
indicating that the HSC-to-MK pathway can be noticeably faster than 
pathways producing other lineages (22). Our results suggest that 
pMKPs are likely to arise independently of the MPP2 stage, as sui-
cidal depletion of the earliest HSPCs reduces pMKPs to a much 
greater extent than MPP2s. It is therefore tempting to speculate that 
our pMKP sort scheme may isolate intermediate cells on this shorter, 
faster bypass trajectory. A recent study of JAK2 V617F-driven MF 
in humans attributed increased megakaryopoiesis to the expansion 
of both traditional MkPs and a novel MkP-like population, suggest-
ing that cells that may be analogous to our pMKPs are relevant in 
human disease (30).
We also investigated an outstanding question about at which 
stages mutant CALR acts to drive a platelet phenotype. Mutant CALR 
has been demonstrated to increase the number of immunophenotypic 
HSCs and MkPs (6), and we also saw an expansion in the number of 
pMKPs. When considering the behavior of cells individually, it is 
clear that mutant CALR acts from the stem cell compartment: CALR 
DEL HOM HSCs were more proliferative and faster to produce 
megakaryocytes than were their WT counterparts. Mutant CALR 
did not show a strong effect on the proliferation or MK bias of pMKPs 
at the level of a single cell but drove an increase in proliferation of 
MkPs and thus the number of megakaryocytes produced. We therefore 
concluded that mutant CALR drives platelet bias and proliferation 
at multiple stages of megakaryopoiesis, although this effect is strongest 
within HSCs.
Last, we used our single-cell transcriptomic data to ask which 
biological pathways were most differentially regulated in our CALR 
DEL HOM mice. Mutant CALR was associated with an up-regulation 
of the unfolded protein response, as would be expected for cells 
with impaired chaperone activity and as has been seen in human 
patient cells (34). In addition, mutant CALR cells showed an in-
crease in cell cycle genes, again consistent with observations from 
human patient cells (34) and in agreement with our in vitro data, 
which showed that mutant CALR HSCs and MkPs were more pro-
liferative. We also found up-regulation of cholesterol biosynthesis 
pathway genes in mutant CALR hematopoietic cells. While choles-
terol biosynthesis is broadly increased across numerous cancers (39), 
including hematological cancers (40), CALR has also been directly 
linked to cholesterol biosynthesis. CALR−/− mouse embryonic fi-
broblasts show impaired endoplasmic reticulum (ER) Ca2+ levels, 
leading to overactivation of SREBPs, which then up-regulate cho-
lesterol and triacylglycerol biosynthesis genes (41). As mutant CALR 
lacks its Ca2+-binding domain, it is possible that CALR DEL HOM 
cells phenocopy knockout cells with respect to ER Ca2+ stores, thus 
leading to the observed overactive transcription of cholesterol bio-
synthesis genes. While megakaryocytes derived from human pa-
tient samples have been shown to have increased store-operated 
Ca2+ entry due to the perturbation of a complex between STIM1, 
ERp57, and CALR (42), none of our differentially activated path-
ways from IPA pointed to altered cytoplasmic Ca2+ signaling in the 
stem and progenitor populations tested. This may reflect differences 
between progenitor and mature cells. Mice with impaired choles-
terol efflux have more proliferative HSCs (43) and an increase in 
MkP proliferation and an ET-like phenotype (44), suggesting that 
there may be a previously unknown link between the CALR DEL 
mutation, cholesterol metabolism, proliferation of MkPs, and thus 
the overproduction of platelets. While cholesterol biosynthesis 
was the most prominent novel target found in our transcriptomic 
analysis, it was by no means alone. IPA upstream regulator analy-
sis predicted an up-regulation of interleukin-5 (IL-5), GM-CSF, 
and HGF—all with known roles in hematopoiesis—in addition to 
several unexpected results, such as TBX2, a transcription factor 
that has not been studied in hematopoiesis. Upstream regulators 
predicted to be decreased include the tumor suppressor TP53; 
let-7, a microRNA with a role in the self-renewal of fetal HSCs (45); 
and KDM5B (Jarid1b), a histone methylase required for HSC self- 
renewal (46).
Overall, our study has characterized a previously undescribed MK 
trajectory implicated in the progression of ET. We find that pMKPs are 
an intermediate stage within one pathway of megakaryopoiesis and 
hypothesize that they may be situated within the MPP2-independent 
MK shortcut. Last, our analysis confirmed that JAK-STAT signaling, 
unfolded protein response, and cell cycle are all increased by the pres-
ence of mutant CALR and found up-regulation of cholesterol bio-
synthesis, in addition to numerous other potential upstream regula-
tors. Functional validation of these biological pathways and upstream 
regulators may represent promising avenues of future research to bet-
ter understand mutant CALR-driven disease and in the develop-
ment of therapeutic strategies.
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The objectives of the study were to generate transcriptomic data from 
our CALR mouse model of ET and to use these data to determine 
how the hematopoietic landscape is affected by the CALR DEL mu-
tation. All mouse procedures were performed in strict accordance 
with the U.K. Home Office regulations for animal research under 
project license 70/8406.
FACS sorting
Bone marrow cells were harvested from the femurs, tibia, and iliac 
crests of mice. Bones were crushed in a mortar and pestle in phosphate- 
buffered saline (PBS) and 2% fetal bovine serum (FBS) and 5 mM EDTA 
and then filtered through a 70-m filter to obtain a suspension of 
bone marrow cells. The suspension was incubated with an equal vol-
ume of ammonium chloride solution (STEMCELL Technologies, 
Vancouver, Canada) for 10 min on ice to lyse erythrocytes, followed 
by centrifugation for 5 min at 350g. The cell pellet was resuspended 
in PBS and 2% FBS and 5 mM EDTA, filtered again through a 70-m 
filter, and centrifuged again for 5 min at 350g. For cell sorting exper-
iments, bone marrow mononuclear cell suspensions were immuno-
magnetically depleted of lineage (Lin)–positive cells (EasySep Mouse 
Hematopoietic Progenitor Cell Isolation Kit, catalog no. 19856, 
STEMCELL Technologies). For staining, cells were incubated with 
the indicated antibodies for 40 min on ice; see attached tables for 
catalog information and concentrations used (table S4). Flow cytom-
etry was performed on BD LSRFortessa analyzers, and flow cyto-
metric sorting was performed on BD Influx 4 and 5 cell sorters (BD 
Biosciences, San Jose, USA). Flow data were analyzed using FlowJo 
software (Tree Star, Ashland, USA).
10x data processing and quality control
For 10x Chromium (10x Genomics, Pleasanton, CA) experiments, 
Lin− c-Kit+ (LK) and Lin− Sca1+ cKit+ (LSK) cells were sort purified 
as described above and processed according to the manufacturer’s 
protocol. Sample demultiplexing, barcodes processing, and gene 
counting were performed using the count commands from the Cell 
Ranger v1.3 pipeline (https://support.10xgenomics.com/single-cell- 
gene-expression/software/overview/welcome). After Cell Ranger pro-
cessing, each sample (LK and LSK for WT and CALR HOM DEL) 
was filtered for potential doublets by simulating synthetic doublets 
from pairs of scRNAseq profiles and assigning scores based on a k 
nearest-neighbor classifier on PCA-transformed data. The 1 and 
4.5% of cells with the highest doublets scores from each LSK or LK 
sample were removed from further analysis, respectively. Cells with 
>10% of unique molecular identifier (UMI) counts mapping to mito-
chondrial genes, expressing fewer than 500 genes, or with a total 
number of UMI counts further than 3 SDs from the mean were ex-
cluded. After quality control, 11,098 WT (5139 LK and 5959 LSK) 
and 15,547 HOM (7815 LK and 7732 LSK) cells were retained for 
downstream analysis from our first repeat. For our second repeat, 
3451 WT (2479 LK and 972 LSK) and 12,372 HOM (7824 LK and 
4548 LSK) cells were retained for downstream analysis. These cells 
were then normalized to the same total count. All scRNAseq data 
were analyzed using the Scanpy Python Module (47).
Clustering analysis and mapping
To assign cell type identities to WT and CALR samples, a previously 
published landscape of 45,000 WT LK and LSK hematopoietic pro-
genitors (24) was used as a reference for cell type annotation. This 
reference was clustered using Louvain clustering, resulting in 13 clus-
ters. LK + LSK samples were joined for each genotype (WT and 
CALR DEL HOM) and projected into the PCA space of this refer-
ence dataset. Nearest neighbors were calculated between the two 
datasets based on Euclidean distance in the top 50 PCA components. 
Cells were assigned to the same cluster to which the majority of 
their 15 nearest neighbors in the reference belonged.
Force-directed graph visualization
A force-directed graph visualization of the 45,000 cell reference data-
set was calculated by first constructing a k = 7 nearest-neighbor graph 
from the data, which was then used as input for the ForceAtlas2 
algorithm as implemented in Gephi 0.9.1 (https://gephi.org). In the 
ForceAtlas2 algorithm, all cells are pushed away from each other, with 
the nearest-neighbor connections pulling them back together to 
segregate separate trajectories.
PAGA graph visualization
A fine-resolution clustering of the reference dataset was calculated 
using the Louvain algorithm, resulting in 63 clusters. These were 
used as input for a PAGA analysis of the reference dataset using the 
Scanpy Python Module with default parameters. The results of the 
PAGA analysis were visualized by using the nodes and their edge 
weights as input into the ForceAtlas2 algorithm for calculating force- 
directed graphs as implemented in Gephi 0.9.1. For visualization, 
only connections with edge weights of >0.3 were shown.
Marker gene expression on PAGA graph
To visualize gene expression of the PAGA graph, the mean normal-
ized expression of all cells belonging to each node was calculated and 
displayed on a per-node basis.
Differential abundance analysis
To calculate differential abundances, votes were given out from each 
WT LK and CALR LK cell to their k-nearest neighbors in the refer-
ence dataset, with k chosen such that the total number of votes given 
out by each sample was the same. For each cell in the reference data-
set, the difference between the number of votes received from the 
WT and CALR HOM samples was calculated. This difference acts 
as a proxy for the differential abundance of WT and CALR HOM 
cells for the region of the LK landscape in which the reference cell is 
located. This differential abundance proxy could then be visualized 
either on the reference landscape itself or on the PAGA graph cal-
culated using the reference landscape. In the latter case, each node 
of the PAGA graph was colored by the mean differential abundance 
of all cells belonging to that node.
In vitro cell culture
After flow sorting, cells were cultured in StemSpan SFEM (serum-free 
expansion medium) (STEMCELL Technologies) supplemented with 
10% FBS (STEMCELL Technologies), 1% penicillin/streptomycin 
(Sigma-Aldrich), 1% l-glutamine (Sigma-Aldrich), stem cell factor 
(SCF; 250 ng/ml), IL-3 (10 ng/ml), and IL-6 (10 ng/ml; STEMCELL 
Technologies), with or without thrombopoietin (100 ng/ml; STEMCELL 
Technologies), in round- bottom 96-well plates (Corning, Corning, 
USA). For pro-erythroid conditions, cells were cultured as above but 
with the following cytokines: SCF (250 ng/ml), THPO (thrombopoietin) 
(50 ng/ml), EPO (erythropoietin) (5 U/ml), IL-3 (20 ng/ml), and 
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Flt3L (50 ng/ml). For pro-myeloid conditions, cells were cultured as 
above but with the following cytokines: SCF (250 ng/ml), THPO 
(50 ng/ml), granulocyte colony-stimulating factor (50 ng/ml), IL-3 
(20 ng/ml), Flt3L (50 ng/ml), and GM-CSF (50 ng/ml).
Classification of single-cell clones
At 1, 2, 3, 4, and, in some cases, 7 days after flow sorting, single 
cell–derived clones were visually inspected. Wells with surviving cells 
were classified into one of four categories: (i) exactly one enlarged 
cell, presumed to be a megakaryocyte; (ii) multiple enlarged cells; 
(iii) mixed expansion, with both small and enlarged cells; and (iv) 
expansion with only small cells. In some cases, the experimenter was 
blinded to the identity of the cell population initially sorted into the 
well he/she was inspecting and the genotype of the mouse.
Fluorescence microscopy
For immunofluorescence, cells were allowed to adhere to the surface 
of poly-l-lysine–coated slides for 30 min at 37°C (Poly-Prep Slides, 
Sigma-Aldrich). Cells were then fixed with 4% paraformaldehyde 
(Sigma-Aldrich) in PBS overnight at 4°C, permeabilized with 0.25% 
Triton X-100 (Sigma-Aldrich) in PBS for 10 min at room temperature, 
and blocked with 1% bovine serum albumin (Sigma-Aldrich) for 
1 hour at room temperature. Cells were stained with CD41 Alexa 
Fluor 488 (BioLegend, catalog no. 133908) overnight and mounted 
with 4′,6-diamidino-2-phenylindole (DAPI) (VECTASHIELD Mount-
ing Medium with DAPI, Vector Laboratories Inc., Burlingame, USA; 
catalog no. H-1500). Pictures were acquired on LSM-710 and LSM-
780 confocal microscopes (Zeiss) and analyzed using ZEN software 
(Zeiss). For quantification of immunofluorescence, cells were cul-
tured on CD44-coated glass-bottom plates for immobilization (48), 
followed by fixation and staining as above. Pictures were acquired 
on a Leica DMI4000 microscope (Leica), and CD41 intensity and 
cell size were quantified using Fiji software.
Bone marrow transplantation
FACS-sorted cells from VWF-GFP+ donors were injected into the 
tail veins of W41/W41 (CD45.1) recipient that had been sublethally 
irradiated with 1 × 400 centigrays with 250,000 spleen cells as helpers. 
Peripheral blood was analyzed 1, 2, 3, 4, and 16 weeks after trans-
plant for all cohorts.
Differential gene expression
Differential expression analysis was performed between WT (LK + LSK) 
and CALR DEL HOM (LK + LSK) clusters using the Wilcoxon rank sum 
test on all genes that passed initial quality control (typically approx-
imately 15,000). A Benjamini-Hochberg correction was applied to 
correct for multiple testing. Genes with an adjusted P value of <0.05 and 
a fold change of >1.5 between genotypes were marked as differentially 
expressed. The original normalized counts were used in all cases.
Ingenuity Pathway Analysis
DEGs were studied using IPA (Qiagen). We imputed the whole 
transcriptome in IPA and then filtered for analysis only statisti-
cally significant (adjusted P < 0.01) items with a log2FC > 0.3785 or 
log2FC < −0.3785. “Pathways” and “upstream regulator” networks 
showing relationships and interactions experimentally confirmed 
between DEGs and others that functionally interact with them were 
generated and ranked in terms of significance of participating genes 
(P < 0.05) and activation status (z score).
Statistical analysis
Data were analyzed, and graphs were generated in Microsoft Excel 
(Microsoft) and GraphPad PRISM (GraphPad, La Jolla, USA). Data 
are presented as means ± SD. Unless otherwise stated, statistical tests 
were unpaired Student’s t tests. P values are as follows: *P < 0.05, 
**P < 0.01, ***P < 0.001, and ****P < 0.0001.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/6/48/eabd3139/DC1
View/request a protocol for this paper from Bio-protocol.
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